Fipronil + (S)-Methoprene + Pyriproxyfen

Verify with FDA CVM →

40 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
40
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Fipronil + (S)-Methoprene + Pyriproxyfen

Administration Routes

TopicalUnknownOther

Species Affected

Dog 33
Cat 7

Most Affected Breeds

Crossbred Canine/dog 5
Domestic Shorthair 3
Retriever - Labrador 3
Shepherd Dog - German 3
Terrier - Yorkshire 3
Domestic Longhair 2
Shepherd Dog - Australian 2
Retriever - Golden 2
Persian 2
Beagle 2

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 8
Other abnormal test result NOS 8
Vomiting 7
Lethargy (see also Central nervous system depression in 'Neurological') 6
Enlarged liver 4
Elevated serum alkaline phosphatase (SAP) 3
Licking 3
Agitation 3
INEFFECTIVE, HOOKS 3
Shaking 3
Weakness 3
Lack of efficacy (ectoparasite) - flea 2

Outcome Breakdown

Outcome Unknown
22 (55.0%)
Recovered/Normal
9 (22.5%)
Ongoing
9 (22.5%)

Data Summary

Metric Value
Total adverse event reports 40
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Fipronil + (S)-Methoprene + Pyriproxyfen Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 40 adverse event reports referencing Fipronil + (S)-Methoprene + Pyriproxyfen, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Fipronil + (S)-Methoprene + Pyriproxyfen. Reported administration routes include Topical, Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Fipronil + (S)-Methoprene + Pyriproxyfen reports are Dog (33 reports), Cat (7 reports), with Dog accounting for the largest share. Within those species, Crossbred Canine/dog (5), Domestic Shorthair (3), Retriever - Labrador (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Fipronil + (S)-Methoprene + Pyriproxyfen are Lack of efficacy (endoparasite) - heartworm (8), Other abnormal test result NOS (8), Vomiting (7), Lethargy (see also Central nervous system depression in 'Neurological') (6). Of the 40 reports with a coded outcome, Outcome Unknown is the leading category at 55.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Fipronil + (S)-Methoprene + Pyriproxyfen.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial